A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-06. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
=== Professional directories === The IIR publishes two professional directories: a Laboratory Directory, which lists more than 300 laboratories in 55 countries; an Expertise Directory, which lists over 300 international experts in the refrigeration sector.
Rogers (2010) defines five major criteria that explain differences in the acceptance of new technology by consumers: complexity, compatibility, relative advantage, trialability and observability. Acceptance of innovative technologies can be improved by providing non-emotional and concise information about these new technological processes methods. The HighTech project also suggests that written information has a higher impact on consumers than audio-visual information.
== Incumbents == Lord Lieutenant of Anglesey – Henry Paget Lord Lieutenant of Brecknockshire and Monmouthshire – Henry Somerset, 6th Duke of Beaufort Lord Lieutenant of Caernarvonshire – Thomas Bulkeley, 7th Viscount Bulkeley Lord Lieutenant of Cardiganshire – Thomas Johnes Lord Lieutenant of Carmarthenshire – John Vaughan (until 19 January); George Rice, 3rd Baron Dynevor (from 21 April) Lord Lieutenant of Denbighshire – Sir Watkin Williams-Wynn, 5th Baronet Lord Lieutenant of Flintshire – Robert Grosvenor, 1st Marquess of Westminster Lord Lieutenant of Glamorgan – John Stuart, 1st Marquess of Bute Lord Lieutenant of Merionethshire - Sir Watkin Williams-Wynn, 5th Baronet Lord Lieutenant of Montgomeryshire – Edward Clive, 1st Earl of Powis Lord Lieutenant of Pembrokeshire – Richard Philipps, 1st Baron Milford Lord Lieutenant of Radnorshire – George Rodney, 3rd Baron Rodney Bishop of Bangor – William Cleaver Bishop of Llandaff – Richard Watson Bishop of St Asaph – Samuel Horsley Bishop of St Davids – Thomas Burgess
In series 3, Kenny is said to have helped Eric through a drinking problem following Eric's marital separation. Kenny also reveals he recently got married himself. Eric admits to Yasmin that he regrets showing Kenny a vulnerable side of himself. Eric, recently promoted to partner, is told by Adler that he needs to fire someone on the trading floor to prove his worth. Instead of firing Yasmin or Robert like he initially considered, Eric fires Kenny, threatening to expose his past treatment of Yasmin if he does not go quietly. Kenny is later shown to have joined Goldman Sachs alongside fellow ex-Pierpoint employees Daria Greenock and Jackie Walsh, and the three agree to help Harper short Pierpoint. In series 4, Kenny now works at Deutsche Bank, and Harper and Eric, now running their own hedge fund, enlist him to broker their short of payment processing startup Tender. Eric apologizes to Kenny for firing him. Kenny later tells Harper and Eric that they have breached their risk limits due to Tender's share price continuing to rise, forcing Deutsche to issue a margin call on their firm. Harper liquidates several of her firm's other positions to post more collateral, and sends Sweetpea and Kwabena to Accra in a last-ditch effort to uncover evidence against Tender. The Tender short is ultimately successful, and Harper calls Kenny to close the position after Tender's stock plummets, netting SternTao £110 million.
Sources: en.wikipedia.org
=== Approval history === On 22 December 2009, a New Drug Application (NDA) was submitted to the Food and Drug Administration (FDA) in the United States. On 16 September 2010, an FDA advisory panel voted 9–5 against approval of the drug based on concerns over both efficacy and safety, particularly the findings of mammary gland tumors of female rats. On 23 October 2010, the FDA decided not to approve the drug based on the available data. This was not only because cancer promoting properties could not be ruled out, but also because the weight loss efficacy was considered "marginal". On 10 May 2012, after a new round of studies submitted by Arena, an FDA panel voted to recommend lorcaserin with certain restrictions and patient monitoring. The restrictions include patients with a BMI of over 30, or with a BMI over 27 and a comorbidity such as high blood pressure or type 2 diabetes. On 27 June 2012, the FDA approved lorcaserin for use in adults with a body mass index (BMI) of 30 or greater (obese), or adults with a BMI of 27 or greater (overweight) and who had at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia). On 15 July 2016, the FDA approved the extended release version of lorcaserin for weight management with once-daily dosing instead of twice daily dosing. On 17 September 2020, the FDA withdrew approval for lorcaserin and for extended-release lorcaserin tablets.
The 2014 Ebola outbreak killed more than 11,300 people. In the Democratic Republic of Congo (DRC), as of January 2020, this is the second largest outbreak with over 3,400 confirmed or probable cases, including more than 2,200 deaths. Regeneron used its VelociGene, VelocImmune, and VelociMab antibody discovery and production technologies and coordinated with the U.S. government's Biomedical Advanced Research and Development Authority (BARDA). The therapy was developed in 6 months and a Phase 1 trial in healthy humans was completed in 2015.
== Hazards == Americium-241 has the same general hazards as other americium isotopes: it is both extremely toxic and radioactive. Though α-particles can be stopped by a sheet of paper, there are serious health concerns for ingestion of α-emitters. Americium and its isotopes are also very chemically toxic as well, in the form of heavy-metal toxicity. As little as 0.03 microcuries (1.1 kBq) is the maximum permissible body burden for 241Am. Americium-241 is an α-emitter with a weak γ-ray byproduct. Safely handling americium-241 requires knowing and following proper safety precautions, as without them it would be extremely dangerous. Its specific gamma dose constant is 3.14×10−1 mR/hr/mCi or 8.48×10−5 mSv/hr/MBq at 1 metre (3 ft 3 in). If consumed, americium-241 is excreted within a few days and only 0.05% is absorbed in the blood. From there, roughly 45% of it goes to the liver and 45% to the bones, and the remaining 10% is excreted. The uptake to the liver depends on the individual and increases with age. In the bones, americium is first deposited over cortical and trabecular surfaces and slowly redistributes over the bone with time. The biological half-life of 241Am is 50 years in the bones and 20 years in the liver, whereas in the gonads (testicles and ovaries) it remains permanently; in all these organs, americium promotes formation of cancer cells as a result of its radioactivity.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.